Abstract
The CCL2 chemokine receptor CCR2 drives cancer by mediating recruitment of monocytes and myeloid-derived suppressor cells to the tumor microenvironment. In this study, we extend the significance of CCR2 in this setting by identifying a new role for it in mediating recruitment of CD4 
Introduction
Chemokine-chemokine receptor interactions play major roles in the shaping of the tumor microenvironment (TME). These interactions can induce the differential recruitment of immune cells and by this mean turn the TME into an immunosuppressive site (1, 2) . CCR2, a chemokine receptor highly expressed by inflammatory monocytes, is crucial for the recruitment of the latter from the bone marrow to inflamed tissues (3) but also displays chemotactic properties for T-cells (4, 5) . Secretion of the major CCR2 ligand (CCL2) by both the tumor and tumor-stromal cells is common in many tumor types in both human and mouse models (6, 7) . For these reasons the CCR2-CCL2 axis is an important mechanistic marker of tumor development (8) and can also predict clinical benefit after cancer therapy (6) . Beyond tumor-associated myeloid cells, (12) both in draining lymph nodes (dLN) (13) or in the tumor itself (9) . A better understanding of the mechanisms involved in Tregs trafficking and accumulation within the TME is thus needed.
Tregs display different homing properties and their appropriate compartmentalization is crucial for their in vivo activity (14, 15) . Following thymus emigration, Tregs can enter secondary lymphoid organs in a CCR7, CD62L dependent fashion. This lineage can be maintained throughout time by further recruitment or by continuous selfrenewal (16) . Activation and antigen priming in secondary lymphoid organs promote down-regulation of CCR7 and CD62L while other memory/effector type trafficking receptors may be upregulated to allow Tregs to migrate into non-lymphoid or inflamed tissues (14, (17) (18) (19) . To date, few chemokine receptors have been associated with the tumor homing properties of Tregs, though a role for CCL22 in the recruitment of CCR4 + Tregs into human ovarian and/or breast cancer has been described (20) (21) (22) .
CCL2 is described as a pro-inflammatory cytokine, but contradictory functions have been observed in the absence of CCR2 in non-infectious inflammatory models (23, 24) .
A dual role for CCR2 was described in a model of arthritis because a subset of highly suppressive Treg, expressing CCR2, expanded during the course of the disease (24) .
The chemokine receptors CCR2, CCR4 and CCR5 and P-and E-selectins were all necessary to ensure efficient homing of Tregs to a graft tissue (25) . Finally, in a model of delayed-type hypersensitivity reaction, antigen-specific Tregs required CCR2 to migrate toward the antigen site (26) . All together, these findings support a role for CCR2 in the homing of activated Tregs to an inflamed site.
We therefore hypothesized that CCR2 expression on Tregs might play a central role in tumor context. Herein, we studied the role of CCR2 on the compartmentalization and the dynamic of Tregs in different tumor models, as well as, human oral squamous cell carcinoma (OSCC). We showed that CCR2 + Tregs represent a discrete subset that is highly important for suppressing anti-tumor responses. Finally, we observed a selective depletion of this subset by low-dose cyclophosphamide (CP) which provides new interpretation in the Treg mediated effect of CP treatment.
Material and Methods

Ethical statement
All experiment protocols were approved by the French animal experimentation and Gingival tissues (n=10) were collected from healthy subjects undergoing preventive wisdom tooth extraction (Odontology department, Pitié-Salpêtrière Hospital; Paris, France). Control blood samples (n=42) were obtained from volunteer healthy donors (Etablissement Francais du Sang, Paris, France). The male to female ratio was 1.7:1 for OSCC blood patients (mean age 60.8±10 years); 1.9:1 (mean age 51.6±18.1 years) for control blood and 2.5:1 for tumors patients (mean age 62.5±8.9 years); 1.5:1 for gingival tissues (mean age 40.2±18 years). 
Cells
The MCA-OVA cell line (kindly provided by Dr. C. Théry, Institut Curie, Paris France) is stably transfected with a plasmid encoding for soluble ovalbumin (OVA) (29) . MCA- 
ELISA
Plasma, tumor and lymph node tissues were harvested on indicated days, stored in PBS at -80°C, thawed and centrifuged to obtain tissue homogenates. Murine CCL2 ELISA was performed using Quantikine ELISA Mouse Immunoassay kits (Bio-techne) following the manufacturer's protocol.
Flow cytometry
Phenotypic characterization of all murine cell populations was performed using either 
Supplemental information
Additional information can be found in Supplementary Material and Methods.
Results
CCR2 expression on Tregs is required for tumor-infiltration
We first examined the impact of CCR2 invalidation on tumor growth and on the These results indicated that CCR2 contributed to increasing the dynamic of Tregs within the dLN and might reflect Tregs emigration from the dLN toward the tumor.
CCR2 + Tregs accumulate during tumor development
We next investigated whether Tregs express the CCR2 receptor at their surface. CCR2 staining using the antibody that labeled inflammatory monocytes was not detected on Treg. CCR2 is the best known receptor for the chemokine CCL2 and presents high affinity for this chemokine. Using the CCR2 ligand, conjugated with Alexa-647 dye Figure 2B ). In contrast, the proportion of CCR2 + Th did not significantly increase in those tissues over time (Figure 2A-B) . In the tumor, the proportion of CCR2 Figure 4) . We conclude that CCR2 + Tregs are preferentially targeted by low-dose CP due to their higher activating and proliferating state, and that in the absence of CCR2, non-cycling Tregs are retained in the dLN leading to lower depletion after CP treatment.
Low-dose CP fails to enhance the priming of OT-1 in the dLN of Ccr2 -/-mice.
We previously showed that low-dose CP treatment transiently enhances anti-tumor (*p<0.05,**p<0.01,***p<0.001). 
Supplementary Methods
Multiphoton imaging
All imaging experiments were performed on explanted tissue. LNs were carefully collected and were immobilized in an imaging chamber perfused with oxygenated (95% O2 plus 5% CO2) RPMI medium containing 10% FCS. Local temperature was monitored and maintained at 37°C. Lymph node imaging was performed 10 days after tumor inoculation. T cells could be detected up to 200 μm from the surface of LNs.
Measurements were performed in at least three independent experiments.
The two-photon laser scanning microscopy (TPLSM) setup used was a Zeiss LSM 710 
